- CEO
- Hermit Zhang
- Full Time Employees
- 553
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 182, Beijing Road Chengdu SI China 610100
- IPO Date
- Jun 16, 2020
- Business
- Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) engages in the research, development, production, sale, and technical services of preventive biological products, primarily human vaccines, from its headquarters at No. 182 Beijing Road in Chengdu Economic and Technological Development Zone, China, where it was founded in 2004. The company operates GMP-certified facilities including a world-class biotechnology experimental center, SPF experimental animal center, and high-tech workshops for bacterial and viral vaccines, serving domestic markets with nationwide distribution and select exports. Its core marketed products comprise Group ACYW135 Meningococcal Polysaccharide Vaccine (Maikexin) for preventing meningococcal disease; freeze-dried Rabies Vaccine (human diploid cell, HDCV), China's first domestically developed premium rabies vaccine with over a decade of safe use; alongside an advancing pipeline featuring recombinant hexavalent norovirus vaccine (licensed overseas to HilleVax), tetravalent influenza vaccine in clinical stages, herpes zoster vaccine in preclinical development, and others across prophylactic, mRNA, conjugated, inactivated, and polysaccharide categories. In July 2025, Shanghai Healthcare M&A Fund, managed by SIIC Capital, announced a strategic agreement to acquire the company, aiming to accelerate sales of mature products like the rabies vaccine, expand the diversified vaccine pipeline, integrate Shanghai's R&D resources with Chengdu's manufacturing strengths, and establish a fully integrated vaccine ecosystem through commercialization and innovation synergies; additionally, Shanghai Wankexin Biotechnology Partnership signed a share transfer agreement for a 21.91% stake. Kanghua maintains over 100 patented technologies, has undertaken multiple scientific projects, and holds certifications from China's National Medical Products Administration, positioning it as a key player in China's biopharmaceutical sector focused on high-barrier public health vaccines.